

**PERSONAL INFORMATION**



**BĂLAȘA RODICA**

**WORK EXPERIENCE**

**2017 – PRESENT**

**Director of Doctoral School - (I.O.S.U.D)**

University of Medicine, Pharmacy, Science and Technology „George Emil Palade” of Targu Mures (UMFST), Romania

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania

**2017 – PRESENT**

**University Professor Habil (MENCs order, no. 3708/13.04.2017)**

University of Medicine, Pharmacy, Science and Technology „George Emil Palade” of Targu Mures (UMFST), Romania

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania

**2015 - PRESENT**

**University Professor**

Neurology Department, University of Medicine, Pharmacy, Science and Technology „George Emil Palade” of Targu Mures (UMFST), Romania

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania  
Complex didactic activity - classes, internships and practical sessions with students from the Romanian and English sections, 5th year general medicine, 3rd year balneo and kinetotherapy (BKT), 1st year BKT bachelor studies, coordinator for the junior neurologists (years 1-5) and research ( grant director, principal investigator in multicentric studies.

**2006 - PRESENT**

**Head of Neurology 1 Clinic (decision no.236/ 2006)**

Neurology 1 Clinic, Emergency Clinical County Hospital Targu Mures.

- Gheorghe Marinescu Str, No. 50, 540136, Targu Mures (Romania)

**2003 - PRESENT**

**Senior neurologist (Order of MS 846/12.09.2003, no. VIII/d/MB/3107 from 15.09.2003)**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

- Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

**2005 - PRESENT**

**Neurology headmaster (appointed by the meeting of the UMF Senate Bureau Targu Mures, no. 8277 / 24 oct. 2005)**

University of Medicine and Pharmacy of Targu Mures, Neurology, Department M4

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania  
Guidance and coordination of the university and post-university education.

**2017 – PRESENT****Coordinator of the national programme for neurological disorders – Multiple Sclerosis**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

**2017 – PRESENT****Coordinator of the national programme for rare neurological disorders – treatment of patients with acute degenerative and inflammatory-immune pathologies**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

**2017 - PRESENT****Coordinator of the national programme for rare neurological disorders – treatment of patients with chronic degenerative and inflammatory – immune pathologies**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

**2012 – PRESENT****Coordinator of the national programme of fibrinolysis therapy for ischemic stroke (AP-AVC)**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

**2009 – PRESENT****Coordinator of the national programme of diagnosis and treatment for rare diseases and severe sepsis – Myasthenia Gravis**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

**2005 – PRESENT****Coordinator of the regional center for multiple sclerosis treatment**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

**EDUCATION AND TRAINING**

- |                     |   |
|---------------------|---|
| <b>1984-1988</b>    | <b>Graduate of the Unirea Theoretical Lyceum, Targu Mures, Baccalaureate Diploma, F Series, no. 39184, average grade 9.71</b>   |
| <b>1988-1994</b>    | <b>General medicine/Doctor, Student/Licence diploma (series and no. M 000515/1994), Head of the promotion, average grade 10 (transcript no. 6633)</b><br>UMF Targu Mures                                  |
| <b>1994-1999</b>    | <b>Intern doctor/position 41 out of 1087 (MS address no.VIII/B/22540/1994)</b><br>National residency contest 1994, University of Medicine and Pharmacy Carol Davila, Bucharest                            |
| <b>1996-2003</b>    | <b>Doctor in medical sciences PHD (C series, no. 0008787, MEC order no. 4741/25.08.2003), CUM LAUDE in Medicine, Neurology</b><br>UMF Targu Mures   |
| <b>2000-2003</b>    | <b>Junior neurologist /average grade 10 (MS address no. VIII/B/GH/8627/10.12.1999)</b><br>Specialist/junior neurologist competition 2000, University of Medicine and Pharmacy Iuliu Hațeganu, Cluj-Napoca |
| <b>2006-2006</b>    | <b>Master (MEC diploma, F series, no. 0017884), Security, Health and Work Relations Management</b><br>Lucian Blaga University, Sibiu  |
| <b>2003-PRESENT</b> | <b>Primary Physician, average grade 9.77 (MS address no. VIII/d/MB/3107/15.09.2003)</b><br>Primary Physician contest, 2003, University of Medicine and Pharmacy Carol Davila, Bucharest                   |
| <b>1995-1998</b>    | <b>Associate Instructor (UMF Targu Mures, no.102 / 16.03.1995)</b><br>UMF Targu Mures, Neurology, M4 Department   |
| <b>1999-2003</b>    | <b>Assistant professor ( UMF Targu Mures, no. 4630 /1999 )</b><br>UMF Targu Mures, Neurology, M4 Department   |
| <b>2004-2007</b>    | <b>Lecturer (MEC order no. 9594 / 11.04.2004, UMF Senate decision, Targu Mures no. 86/ 2004 )</b><br>UMF Targu Mures, Neurology, M4 Department  |
| <b>2007-2015</b>    | <b>Associate Professor (decision no.300/13.09.2007)</b><br>UMF Targu Mures, Neurology, M4 Department  |

**PERSONAL SKILLS**

Mother tongue Romanian

Foreign Languages

	UNDERSTANDING		SPEAKING		WRITING
	LISTENING	READING	SPOKEN INTERACTION	SPOKEN PRODUCTION	
ENGLISH	C1	C1	C1	C1	B2
FRENCH	C2	C2	C2	C2	B2

**Organisational / managerial skills**

Head of clinic - Neurology 1 Clinic of the Emergency Clinical County Hospital, Targu Mures,  
 Headmaster of the Neurology Department, UMFST Targu Mures, Faculty of Medicine in English  
 Director of the doctoral school (I.O.S.U.D.)  
 Head of the Committee responsible for learning quality in the UMF Targu Mures Senate.  
 Responsible for a team of 7 researchers  
 Responsible for Good Clinical Practice guidelines in the Neurology 1 Clinic of the Emergency Clinical County Hospital, Targu Mures,

**ADDITIONAL INFORMATION**

**A. RESEARCH GRANTS**

**I.1. National Research Grants – project manager**

**I.1.1** The role of cytokines in the immunopathogenesis of multiple sclerosis/autoimmune experimental encephalomyelitis and the evaluation of the immunomodulatory therapy using biomarkers, COMPETITION FOR COLLECTIVE SCIENTIFIC RESEARCH GRANTS, 2014, UMF Targu Mures, Contract No: 18/2015, amount 90000 RON, duration 2014-2016.

**I.1.2** The role of cytokines in the heterogenous response of patients with multiple sclerosis to the immunomodulatory therapy, C COMPETITION FOR COLLECTIVE SCIENTIFIC RESEARCH GRANTS FINANCED EXCLUSIVELY BY PRIVATE FUNDS, session 2014, UMF Targu Mures, Contract No: 16171/2014, amount 23000 RON, duration 2014-2015.

**I.1.3** Regional controlled hypothermia in therapeutical purposes, CNCSIS code 1346/2006, amount 65000 RON, duration 2006-2008.

**I. NATIONAL RESEARCH GRANTS WON BY COMPETITION**

**I.2 National Research Grants – team member:**

**I.2.1** The study of chemokine CXCL 13, early diagnostic marker in Lyme neuroborreliosis versus other infections of the nervous system, COMPETITION FOR COLLECTIVE SCIENTIFIC RESEARCH GRANTS FINANCED EXCLUSIVELY BY PRIVATE FUNDS, 2014, UMF Targu Mures, Contract No: 13894/2014, amount: 25000 RON, duration: 2014-2015.

**I.2.2** Grant CNCSIS Capacitati modul I No. 191 (CP/I/2007): A pilot centre to monitor the pharmacotherapy after pharmacokinetic criteria within the Drug Testing Laboratory Univ.Med.Pharm. Targu Mures (amount 933000 RON, duration: 2007-2009).

**I.2.3** Technical expert in the Advanced centre of medical and pharmaceutical research, POS CCE-AXA II, Operation 2.2.1, ID18827, Contract No: 659/2014, amount 37000000 RON, run time 2014-2015

**I.2.4** Partner in the “Formare pentru Obținerea de Competențe Unitare în Structurile implicate în Îngrijirea pacientului cu Accident Vascular Cerebral – FOCUS AVC”, Contract No. 728/10/06.2024, ammount: 73.649.172,86 RON, duration 2024-2028.

**II. INTERNATIONAL RESEARCH GRANTS****I.3. National Research Grant – mentor:**

**I.3.1.** The role of microbiota in clinical evolution of multiple sclerosis treated with interferon – beta: a comprehensive approach [MICRO-MS], UEFISCDI PD Grant, 2022, PD 80/18.04.2022, PN-III-P1-1.1-PD-2021-0547, amount 50.000 EUR, Project Director – Barcutean Laura Iulia.

**International Research Grants – Project Manager**

**II.1** Experimental model of peripheral mononuclear cells serum biomarkers for Cladribine treatment response in patients with relapsing-remitting multiple sclerosis: a step towards personalised treatment. Regional Grant for Central and Eastern European Countries 2017 Research Project, Project No: 6943/12.07.2018, amount 100.000 EUR, duration: 2018-2020.

**II.2** Assessment of IL-17A, IL-10 and TGF- $\beta$  serum titres in RRMS patients treated with Avonex, possible biomarkers for treatment response and the impact on them of treatment with Avonex, Project No: 1442 / 2014, Amount: 23900 RON, duration: 2014-2015.

**III. POST-DOCTORAL RESEARCHER**

**III.** Postdoctoral research in the program: Supporting research by training specialists within post-doctoral studies programmes, with the following research theme: Heterogeneous responses of immunomodulatory therapies in patients with MS. Contract No: POSDRU/89/1.5/S/64109.

**IV. NATIONAL GRANTS APPLIED FOR, ELIGIBLE, UNFUNDED**

**IV.1** Implementing new, modern interventional methods in the treatment of acute ischaemic stroke: from intraarterial thrombolysis to neurorehabilitation. UEFISCSU, Partner programme, competition 2013, PN-II-PT-PCCA-2013-4-0764. Institution: UMF Targu Mures, amount 400000 EURO, points: 70.

**IV.2** The role of biomarkers in inflammatory processes/degenerative processes in MS: Implications upon the heterogenous MS response and the response to immunomodulatory therapies. Internal competition for collective clinical studies, 2013, UMF POS-TGM-CC-13-01-V-01, amount 90000 RON, points: 84.5

**V. NATIONAL AND INTERNATIONAL RESEARCH GRANTS, APPLIED FOR.****V.1 (National)**

1. Evaluarea mirna din exosomi ca biomarker pentru monitorizarea răspunsului la tratament la pacienții cu scleroză multiplă: studiu practic-explorator. PN-III-P4-PCE-2021-0952.
2. ARNM exozomal ca biomarker pentru raspunsul la tratament in scleroza multiplă: un nou cadru practic-explorator in definirea bolilor neurodegenerative. PN-IV-P1-PCE-2023-1218.
3. Establishing the Romanian Center of Excellence in Clinical Neuroscience (NeuRoX). T-CoEx-2024-0377.

**V.2 (International)**

1. HORIZON-HLTH-2024-DISEASE-13. Personalized Management Platform For Multiple Sclerosis: A Semi-Supervised Approach To Symptom Evaluation And Remote Intervention. PERSEVERANCE.

**B. COORDINATED BACHELORS DEGREES****B.1. BACHELOR'S DEGREES**

During my career I have coordinated more than 55 studies for UMFST both Romanian and English students

**PHD****B.2. PHD****1.Coordinator**

I am currently coordinating 10 PhD studies.

**2. Awarded PhD**

**Bărcuțean Laura Iulia** – IMMUNE RESPONSE HETEROGENEITY AND CLINICAL EVOLUTION OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH INTERFERON BETA OVER A DECADE (“Summa Cum Laude”, 2019).

**Andone Răzvan Sebastian** - THE IMPACT OF THE LIPID PROFILE ON STROKE PROGNOSIS

(“Summa Cum Laude”, 2023).

**Razvan Azamfirei** - CHARACTERIZING DELIRIUM IN PEDIATRIC ILL PATIENTS (“Summa Cum Laude, 2023)

**Daniela Părău** – CONTRIBUTIONS ON BOBATH AND VOJTA THERAPY ON MOTOR DEFICIT IN CHILDREN WITH ANTE-, PERI-, AND POSTNATAL DISTRESS („Magna Cum Laude, 2024)

**C. MEMBER IN UMF COMMITTEES FOR DIDACTIC EMPLOYMENT**

I have coordinated several committees for academic employment in UMFST Targu Mures.

**D. NATIONAL AND INTERNATIONAL POST-UNIVERSITARY COURSES – ORGANISATION**

1. EFNS Regional Teaching Course, 27-29 sep, 2007, Sovata;
2. Postuniversity lecture: Disorders in deglutition: aetiology, diagnostic, treatment, 11-12 aug 2014, UMF Targu Mures ;
3. Postuniversity lecture: Neuro-immunology, 20-22 nov 2014, UMF Targu Mures;
4. Postuniversity lecture: Neurodegenerative disorders of the peripheral nervous system – clinical and neurophysiological aspects, 25-26 mar 2021, UMFST Targu Mures.

**E. NATIONAL AND INTERNATIONAL POSTUNIVERSITARY COURSES**

**I. Participation:** I have participated and graduated from more than 30 national and international postuniversity courses.

**II. Organisation:**

1. First International Conference on Innovations in Population Health and Personalized Medicine, 12-13 dec. 2018, Targu Mures.
2. Toward Precision Medicine in Multiple Sclerosis Management, 7-8 oct. 2022, Targu Mures;
3. The 14th National Conference of Clinical Neurophysiology ASNER, 27-29 oct. 2023, Targu Mures (local committee).
4. Toward Precision Medicine in Multiple Sclerosis Management, 24-26 oct 2025, Targu Mures;

**F. ACTIVITY IN NATIONAL AND INTERNATIONAL SCIENTIFIC MANIFESTATIONS**

I have presented more than 50 lectures at various national and international conferences.

**G. SPECIALISATIONS AND ABROAD EXPERIENCES**

1. Neurology Service of Centre Hospitalier Universitaire Pierre Wertheimer, Lyon, France (March 2012), Prof. Dr. Christian Confavreux;
2. Tysabri Training and workshop at the Kantonspitaal St. Gallen, Switzerland;
3. Neurology Service of Centre Hospitalier Universitaire Tours, France (15th dec 1997 – 3rd May 1998), Prof. Dr. Alain Autret;
4. Neurophysiology Service of LHopital de la Salpetriere Paris, France (1st July 1997 – 2nd August 1997 1 month), Prof. Dr. Pierre Bouche;
5. Neurology Service of Centre Hospitalier Universitaire Tourse, France (2nd April 1997 – 30 Jun 1997), Prof. Dr. Alain Autret.

**H. SCIENTIFIC MANIFESTATIONS**

More than 2100 Continuous Medical Education credits.

**I. HONOURS AND AWARDS**

**UEFISCDI: Awards for research articles**

1. CODE: PN-II-RU-PRECISI-2015-9-9728: Jung I, Gurzu S, **Bălașa R**, Moțățăianu A, Contac AO, Halmaciu I, Popescu S, Simu I. A coin-like peripheral small lung carcinoma associated with acute paraneoplastic axonal Guillain-Barré-like syndrome. *Medicine (Baltimore)* 2015; 94: e910. **FI: 4.256.**
2. CODE: PN-III-P1-1.1-PRECISI-2018-26093: Huțanu A, Iancu M, **Bălașa R**, Maier S, Dobreanu M. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. *Acta Pharmacol Sin* 2018; 39: 1228-1236. **FI: 0.99**
3. CODE: PN-III-P1-1.1-PRECISI-2020-51187: Moțățăianu A, Bărcuțean L, **Bălașa R**. Neuroimmunity in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2020, 0: 1-8. DOI: 10.1080/21678421.2019.1708949. **FI: 2.883**

4. CODE: PN-III-P1-1.1-PRECISI-2021-59993: **Balasa R**, Barcutean L, Mosora O, Manu DR. Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. *IJMS*. 2021;22:8370.
5. CODE: PN-III-P1-1.1-PRECISI-2021-59995: Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, Draghici I, Cioban AM, **Balasa R**. Gender Differences in Risk Factor Profile and Clinical Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis. 2021;30:1382.
6. CODE: PN-III-P1-1.1-PRECISI-2021-62209: Forro T, Bajko Z, Balasa A, **Balasa R**. Dysfunction of the Neurovascular Unit in Ischemic Stroke: Highlights on microRNAs and Exosomes as Potential Biomarkers and Therapy. 2021;22:5261.
7. CODE: PN-III-P1-1.1-PRECISI-2021-60213: Andone S, Bajko Z, Motataianu A, Mosora O, **Balasa R**. The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review. 2021;22:9032.
8. PN-IV-P2-2.3-PRECISI-2023-76665: Dobreanu M, Manu DR, Manescu IB, Gabor MR, Hutanu A, Barcutean L, **Balasa R**. Treatment With Cladribine Selects IFN $\gamma$ +IL17+ T Cells in RRMS Patients – An In Vitro Study. *Front Immunol*. 2021; 12:743010.
9. PN-IV-P2-2.3-PRECISI-2023-73041: **Balasa R**, Maier S, Hutanu A, Voidazan S, Andone S, Oiaga M, Manu D. Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients. *Int J Mol Sci*. 2022 Sep 6;23(18):10262.
10. PN-IV-P2-2.3-PRECISI-2023-78021. Andone S, Bajko Z, Motataianu A, Maier S, Barcutean L, Balasa R. Neuroprotection in Stroke-Focus on the Renin-Angiotensin System: A Systematic Review. *Int J Mol Sci*. 2022 Mar 31;23(7):3876.
11. PN-IV-P2-2.3-PRECISI-2023-79545. Stoian A, Stoian M, Bajko Z, Maier S, Andone S, Cioflinc RA, Motataianu A, Barcutean L, Balasa R. Biomedicines. 2022 Mar 25;10(4):774. Autoimmune encephalitis in COVID-19 infection: Our experience and systematic review of the literature.

**American Society for Histocompatibility and Immunogenetics:**

The action of Th17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis, best review paper of 2020 award.

**PHD IN MEDICINE, “CUM LAUDE”;**

Health and Research Ministry Order no. 4741/25.08.2003

**“IN HONORIS” DISTINCTION** – For the support in establishing the Mobile Emergency Service for Resuscitation and Extrication of emergency medical assistance and qualified first-aid integrated system in Romania, celebrating 25 years of SMURD

**RECOMMENDATION from Lawrence Steinman, neurology professor**, Chair of the Department of Neurology and Neurological Sciences, US National Academy of Sciences Stanford University, **Hirsch Index 59**

**DISTINCTION ON BEHALF OF ROMANIAN SOCIETY OF MULTIPLE SCLEROSIS** – for the support given to the multiple sclerosis patients in Romania

**Fellowship of INTERNATIONAL FEDERATION OF CLINICAL NEUROPHYSIOLOGY (IFCN) at th IXth International Congress of EMG and Clinical Neurophysiology**, 7-11 September, 1999, Prague, Czech Republic for the paper: Visual evoked potentials modifiers in multiple sclerosis patients, abstract published in: *Clin Neurophysiol* 1999; 110: S112. IF 2.979, awarded 1000 USD.

**The Order of Medical Merit, in the rank of Knight**, awarded by the President of Romania, Klaus Werner Iohannis; Decree No. 1418/28.11.2024.

**J. MEMBERSHIP IN SCIENTIFIC COMMITTEES OR INTERNATIONAL/NATIONAL SCIENTIFIC SOCIETIES**

**International**

- EFNS Subcommittee multiple sclerosis/demyelinating disease of CNS (2008- 2014);
- EAN Subspecialty Scientific Panel on multiple sclerosis (2014 - present);
- ECTRIMS Council.

**National**

- Member in directorial committee of Romanian Neurology Society (2012-present)
- Corresponding member in the Romanian Academy of Medical Science (2022-present)

**K. FOUNDING MEMBER**

Founding member of the Society for the Study of Diabetic Polyneuropathy, Neurodiab, established in 12 may 2012, Cluj Napoca.

**L. ACADEMIC POSITIONS IN UMFST TARGU MURES**

1. Senate member UMF Targu Mures (2012 – present);
2. Evaluation Committee and Study Quality Assurance President in the UMF Senate Targu Mures (2012 – present);
3. Member in work committee of UMF Targu Mures for obtaining the authorization for medicine in English language (2013 - present);
4. Member in the Ethic Committee in the UMF Senate, Targu Mures;
5. Director of the doctoral school (2017 - present).  
UEFISCDI 2007-2013

**M. EXPERT**

**N. MEMBER IN EDITORIAL AND REDACTIONAL COMMITTEE OF SCIENTIFIC JOURNALS ISI/B+**

**1. ISI Indexed Journals**

- Romanian Journal of Laboratory Medicine (IF 0.171);
- Acta Endocrinologica (IF: 0.45);
- Archives of Medical Research (IF 2.4);
- Expert Review of Neurotherapeutics (IF: 2.834);

**2. B+ Indexed Journals**

- Acta Medica Marisiensis;
- Romanian Journal of Neurology;
- The Journal of Critical Care Medicine.

**O. REVIEWER**

- 2020: Journal of Inflammation Research (IF 4.953)
- 2020: Journal of Neuroimmunology (IF: 3.125)
- 2020: Experimental and Therapeutic Medicine (Special Issue) (IF: 1.785)
- 2020: Health problems of Civilizations

**P. MEMBER IN NATIONAL/INTERNATIONAL SCIENTIFIC SOCIETIES**

**International**

1. European Association of Young Neurologists and Trainees – EAYNT (until 2005);
2. The European Neurological Society - ENS (2003- 2014)
3. European Committee for Treatment and Research in Multiple Sclerosis – ECTRIMS, Council (2009-2012).
4. European Federation of Neurological Societies - EFNS (2003- 2014)
5. European Academy of Neurology - EAN
6. Active corresponding member in American Academy of Neurology - AAN (2007-present)
7. European Stroke Organisation - ESO (2013 - present)
8. Society for the study of Neuroprotection and neuroplasticity (2009 – present)

**National**

1. Active member in Romanian Society of Neurology (SRN) (1996 - present)
2. Active member in Romanian Society of Stroke (AVC) (1998 - present)
3. Active member in Diabetic Neuropathy Society (Neurodiab) (2010 - present)

**Q. REGIONAL COORDINATOR**

1. National treatment programme in neurological diseases
2. National programme for acute interventional therapy in ischemic stroke, AP-AVC

**R. MEMBER OF NATIONAL AND REGIONAL HEALTH COMMITTEES**

**National**

1. Member of the national committee for the treatment of MS (2005 - present);
2. Member in the neurology committee of the Health and Family Ministry (2008-2011, 2013-2014, 2019-Present).

**Regional**

- 1 President of Neurology Committee of County Medical Institution of Mures;
2. President of Speciality Territorial Committee for abroad treatment.

**S. INTERNATIONAL MULTICENTRIC STUDIES**

Principal investigator in numerous international multicentric studies (over 50), ranging from ischemic stroke treatment, Multiple Sclerosis and Parkinson disease

**T. SCIENTIFIC ACTIVITY - PUBLICATIONS**

Impact factor for publications: **285.89**  
Hirsh – **17**  
Citations - **866** (without self-citations), total **1.004**

**U. FIELDS OF INTEREST FOR SCIENTIFIC RESEARCH**

1. Multiple Sclerosis;
2. Cerebrovascular disorders;
3. Parkinson disease;
4. Epilepsy.

**V. SCIENTIFIC ACTIVITY**

1. First author/co-author for 11 monographies and courses (first author of 6 volumes in the last 5 years)
2. First author/co-author for 9 chapters of monographies (first author of 4 in the last 5 years);
3. First author/co-author/principal investigator of more than 300 papers/scientific posters from which:
  - 112 publications ISI/WoS indexed
  - 20 collective publications, ISI indexed
  - 70+ scientific papers (first author/co-author) published in extenso in B+ CNCSIS journals

**W. PUBLICATIONS (ISI indexed)**

1. Farczadi L, Barcutean L, Maier S, **Balasa R**, Imre S. Development and Validation of a New LC-MS/MS Method for the Assay of Plasmatic Peripheral Short- and Medium-Chain Fatty Acids for Metabolomics Applications. *Metabolites*. 2025 Jun 16;15(6):403. IF: 3.7. **Q2**
2. Andone S, Lénárd F, Imre S, Dumitreasa M, **Bălașa R**. Fatty Acid Ratios Versus Conventional Risk Factors in Stroke: Insights into Severe Disability and Mortality Outcomes. *Nutrients*. 2025 Apr 30;17(9):1518. IF: 5.0. **Q1**
3. Moțățăianu A, Mănescu IB, Șerban G, Ion V, **Bălașa R**, Andone S. The Effects of a Mediterranean Diet on Metabolic Hormones and Cytokines in Amyotrophic Lateral Sclerosis Patients: A Prospective Interventional Study. *Nutrients*. 2025 Apr 25;17(9):1437. IF: 5.0. **Q1**
4. Mosora O, Maier S, Manu D, Bărcuțean L, Roman M, Dumitreasă M, **Bălașa R**. Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis. *Int J Mol Sci*. 2025 Apr 20;26(8):3889. IF: 4.9. **Q1**
5. Manu DR, **Bălașa R**, Pruteanu LL, Curean V, Barbu-Tudoran L, Șerban GM, Chinezu R, Bălașa A. Identification of distinct profiles of glioblastoma through the immunocapture of extracellular vesicles from patient plasma. *PLoS One*. 2025 Mar 19;20(3):e0315890. IF: 2.6. **Q2**
6. Șerban GM, Manu D, **Balasa R**, Balasa AF. Extracellular Vesicle-Based Characterization of Stem Cell Phenotype in Glioblastomas. *Cureus*. 2024;28:16(9):ee70403. IF: 1.3.
7. Forró T, Manu DR, Barbu-Tudoran L, **Bălașa R**. Astrocyte Dysfunction Reflected in Ischemia-Induced Astrocyte-Derived Extracellular Vesicles: A Pilot Study on Acute Ischemic Stroke Patients. *Int J Mol Sci*. 2024 Nov 20;25(22):12471. IF: 4.9. **Citations 1. Q1**
8. Maier S, Hutanu A, Barcutean L, Sarmasan E, **Balasa R**. Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients. *RRML* 2024;3. IF:0.5. **Q4**
9. Schenk A, Popa CO, Cojocaru CM, Marian Ș, Maier S, Băjenaru OL, **Bălașa R**. An Online Single-Session Cognitive Behavioral Therapy for Depression and Anxiety Associated with Multiple Sclerosis-Pilot Study. *Behav Sci (Basel)*. 2024 Jul 21;14(7):620. IF: 2.5. **Q2**
10. Schenk A, Popa CO, Cojocaru CM, Marian Ș, Maier S, **Bălașa R**. The Path from Personality to Anxiety and Depression Is Mediated by Cognition in Multiple Sclerosis. *J Pers Med*. 2024 Jun 25;14(7):682. IF: 3. **Q2**
11. Forró T, Manu DR, Băjenaru OL, **Bălașa R**. GFAP as Astrocyte-Derived Extracellular Vesicle Cargo in Acute Ischemic Stroke Patients-A Pilot Study. *Int J Mol Sci*. 2024 May 24;25(11):5726. IF: 4.9. **Citations 1. Q1**
12. Moțățăianu A, Mănescu IB, Șerban G, Bărcuțean L, Ion V, **Bălașa R**, Andone S. Exploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis. *Int J Mol Sci*. 2024 May 7;25(10):5059. IF: 4.9. **Q1**
13. Moțățăianu A, Andone S, Stoian A, **Bălașa R**, Huțanu A, Sărmășan E. A Potential Role of Interleukin-5 in the Pathogenesis and Progression of Amyotrophic Lateral Sclerosis: A New Molecular Perspective. *Int J Mol Sci*. 2024 Mar 28;25(7):3782. IF: 4.9. **Q1**
14. Stoian A, Bajko Z, **Bălașa R**, Andone S, Stoian M, Ormenișan I, Muntean C, Bănescu C. Characteristics of Developmental and Epileptic Encephalopathy Associated with PACS2 p.Glu209Lys Pathogenic Variant-Our Experience and Systematic Review of the Literature. *Biomolecules*. 2024 Feb 23;14(3):270. IF: 4.8. **Citations 1. Q1**
15. Barcutean L, Farczadi L, Manescu IB, Imre S, Maier S, **Balasa R**. Short and Medium Chain Fatty Acids in a Cohort of Naïve Multiple Sclerosis Patients: Pre- and Post-Interferon Beta Treatment Assessment. *Biologics*. 2024 Nov 15;18:349-361. IF:5.3. **Q1**
16. Barcutean L, Maier S, Burai-Patrascu M, Farczadi L, **Balasa R**. The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis. *Int J Mol Sci*. 2024 Mar 11;25(6):3198. IF: 5.6. **Citations 8. Q1**
17. Barcutean L, Maier S, Bajko Z, Stoian A, Mosora O, Sarmasan E, Manescu IB, **Balasa R**. Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression. *J Clin Med*. 2024 Mar 21;13(6):1813. IF: 3.9. **Citations 1. Q2**

18. Parau D, Todoran AB, **Balasa R**. Physiotherapy Intervention on Premature Infants-A Pilot Study. *Medicina (Kaunas)*. 2024 Jan 11;60(1):138. IF: 2.94. **Q1**
19. Parau D, Todoran AB, **Balasa R**. Factors Influencing the Duration of Rehabilitation in Infants with Torticollis-A Pilot Study. *Medicina (Kaunas)*. 2024 Jan 16;60(1):165. IF: 2.94. **Q1**
20. Manu DR, Slevin M, Barcutean L, Forro T, Boghitoiu T, **Balasa R**. Astrocyte Involvement in Blood-Brain Barrier Function: A Critical Update Highlighting Novel, Complex, Neurovascular Interactions. *Int J Mol Sci*. 2023 Dec 5;24(24):17146. IF: 6.20. **Citations 22. Q1**
21. Roman Filip I, Morosanu V, Spinu D, Motoc C, Bajko Z, Sarmasan E, Roman C, **Balasa R**. Cervical Artery Dissections-A Demographical Analysis of Risk Factors, Clinical Characteristics Treatment Procedures, and Outcomes-A Single Centre Study of 54 Consecutive Cases. *J Pers Med*. 2023 Dec 29;14(1):48. IF: 3.50. **Q1**
22. Maier S, Bajkó Z, Roșescu R, Bărcuțean L, Sărmășan E, Voidăzan S, **Bălașa R**. Sociodemographic and Clinical Determinants of Fatigue in Multiple Sclerosis. *Life (Basel)*. 2023 Oct 29;13(11):2132. IF: 3.25. **Citations 4. Q1**
23. Parau D, Todoran AB, Barcutean L, Avram C, **Balasa R**. The Benefits of Combining Bobath and Vojta Therapies in Infants with Motor Development Impairment-A Pilot Study. *Medicina (Kaunas)*. 2023 Oct 23;59(10):1883. doi: 10.3390/medicina59101883. IF: 2.6. **Citations 3. Q1**
24. Morosanu V, **Balasa R**, Morosanu S, Baróti B, Roman-Filip I. Delayed Demyelinating Disease of the Central Nervous System Following Low-Voltage Alternating Current Electrical Injury: A Case Report and Review of the Literature. *Cureus*. 2023 Aug 22;15(8):e43951. IF: 1.2. **ESCI**
25. Barcutean L, Hutanu A, Andone S, Maier S, **Balasa R**. The peripheral profile of the chitinase 3-like-1 in benign multiple sclerosis - a single centre's experience. *CNS Neurol Disord Drug Targets*. 2023 Jun 9. IF: 3.0. **Q3**
26. Stoian A, Bajko Z, Stoian M, Cioflinc RA, Niculescu R, Arbănași EM, Russu E, Botoncea M, **Bălașa R**. The Occurrence of Acute Disseminated Encephalomyelitis in SARS-CoV-2 Infection/Vaccination: Our Experience and a Systematic Review of the Literature. *Vaccines (Basel)*. 2023 Jul 10;11(7):1225. IF: 7.8. **Citations 11. Q1**
27. Roman-Filip I, Morosanu V, Bajko Z, Roman-Filip C, **Balasa R**. Non-Aneurysmal Perimesencephalic Subarachnoid Hemorrhage: A Literature Review. *Diagnostics*. 2023; 13:1195. IF: 3.6. **Citations 3. Q1**
28. Maier S, Barcutean L, Andone S, Manu D, Sarmasan E, Bajko Z, **Balasa R**. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. *IJMS*. 2023;24:4375. IF: 5.6. **Citations 5. Q1**
29. Andone S, Farczadi L, Imre S, Bajko S, Motataianu A, Maier S, Barcutean L, **Balasa R**. Serum Fatty Acids Are Associated with a Higher Risk of Ischemic Stroke. *Nutrients*. 2023; 15:585. IF: 5.9. **Citations 1. Q1**
30. Serban G, Tamas F, **Balasa R**, Manu D, Tamas C, Balasa A. Prognostic Factors of Survival in Glioblastoma Multiforme Patients-A Retrospective Study. *Diagnostics*. 2022;12:2630. IF: 3.6. **Citations 4. Q2**
31. Andone S, Farczádi L, Imre S, **Bălașa R**. Fatty Acids and Lipid Paradox-Neuroprotective Biomarkers in Ischemic Stroke. *Int J Mol Sci*. 2022 Sep 16;23(18):10810. IF: 5.6. **Citations 7. Q1**
32. **Balasa R**, Maier S, Hutanu A, Voidazan S, Andone S, Oiaga M, Manu D. Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients. *IJMS*. 23:10262. IF: 5.6. **Citations 1. Q1**
33. Motataianu A, Serban G, Barcutean L, **Balasa R**. Oxidative Stress in Amyotrophic Lateral Sclerosis: Synergy of Genetic and Environmental Factors. *IJMS*. 2022;23:9339. IF: 5.6. **Citations 29. Q1**
34. Andone S, Bajko Z, Motataianu A, Maier S, Barcutean L, **Balasa R**. Neuroprotection in Stroke – Focus on the renin-angiotensin system: a systematic review. *IJMS*. 2022;23:3876. IF: 6.208. **Citations 8. Q1**
35. Stoian A, Stoian M, Bajko Z, Maier S, Andone S, Cioflinc RA, Motataianu A, Barcutean L, **Balasa R**. Autoimmune encephalitis in COVID-19 infection: Our experience and systematic review of the literature. *Biomedicines*. 2022;25:774. IF 4.75. **Citations 24. Q1**
36. Bajko Z, Maier S, Motataianu A, Filep RC, Stoian A, Andone S, **Balasa R**. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience. *Acta Neurol Belgica*. 2021; ahead of print. DOI: 10.1007/s13760-021-01651-z. FI: 1.98. **Citations: 7. Q3**
37. Tamas F, **Balasa R**, Manu D, Gyorki G, Chinezu R, Tamas C, Balasa A. The importance of small extracellular vesicles in the cerebral metastatic process. *IJMS*. 2022;23:1449. IF: 6.20. **Citations 9. Q1**
38. Tiu C, Teracoasa EO, Tuta S, **Balasa R**, Simu M, Sabau M, Stan A, Radu RA, Tiu V, Casaru B, Negrila A, Panea C. Quality of acute stroke care in Romania: Achievements and gaps between 2017 and 2022. *European Stroke Journal*. 2022;1-8. IF: 5.89. **Citations 8. Q1**

39. Dobreanu M, Manu DR, Manescu IB, Gabor MR, Hutanu A, Barcutean L, **Balasa R**. Treatment With Cladribine Selects IFN $\gamma$ +IL17+ T Cells in RRMS Patients - An In Vitro Study. *Front Immunol*. 2021;12:743010. IF: 8.78. **Citations 2. Q1**
40. Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, Draghici IA, Cioban A, **Balasa R**. Prevalence and clinical characteristics of subclavian steal phenomenon/syndrome in patients with acute ischemic stroke. *J Clin Med*. 2021;10:5237. IF: 4.24. **Citations 6. Q1**
41. Motataianu A, Barcutean L, Bajko Z, Stoian A, Maier S, Voidazan S, **Balasa R**. Autonomic and Somatic Nerve functions in type 2 diabetes mellitus patients: electrophysiological aspects. *Diagnostics*. 2021;11:2005. IF: 3.70. **Citations 5. Q1**
42. Stoian A, **Balasa R**, Grigorescu BL, Maier S, Andone S, Cocuz IG, Bajko Z, Filep CR, Stoian M. Guillain-Barré syndrome associated with Covid-19: A close relationship or just a coincidence? (Review). *Exp Ther Med*. 2021;22:916. IF:2.44. **Citations 8. Q3**
43. **Balasa R**, Barcutean L, Mosora O, Manu D. Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. *Int J Mol Sci*. 2021;22:8370. IF: 5.92. **Citations 76. Q1**
44. Andone S, Bajko Z, Motataianu A, Mosora O, **Balasa R**. The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review. *Int J Mol Sci*. 2021;22:9032. FI: 5.92. **Citations 11. Q1**
45. Bajko Z, **Balasa R**, Maier S, Motataianu A, Barcutean L, Andone S, Stoian A, Filep RC. Stroke secondary to giant-cell arteritis: A literature review. *Exp Ther Med*. 2021 Aug;22(2):876. IF 2.4. **Citations 17. Q4**
46. Stoian A, Bajko Z, Maier S, Cioflinc RA, Grigorescu BL, Motataianu A, Barcutean L, **Balasa R**, Stoian M. High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). 2021;1182. IF: 1.78. **Citations 13. Q4**
47. Mosora O, Barcutean L, **Balasa R**, Fodor R, Maier S, Bajko Z, Stoian A, Motataianu A. Severe Acute Motor Axonal Neuropathy associated with Influenza-A (H1N1) Infection and Prolonged Respiratory Failure - A Case Report. *J Crit Care Med (Targu Mures)*. 2021 Nov 6;7(4):302-307. **ESCI**
48. Forró T, Bajko Z, Balasa A, **Balasa R**. Dysfunction of the Neurovascular Unit in Ischemic Stroke: Highlights on microRNAs and Exosomes as Potential Biomarkers and Therapy. *Int J Mol Sci*. 2021;22:5261. FI: 4.55. **Citations: 30. Q1**
49. Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone Sebastian, Maier S, Draghici IA, Cioban A, **Balasa R**. Gender Differences in Risk Factor Profile and Clinical Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis. *J Clin Med*. 2021;30:1382. DOI: 10.3390/jcm10071382. FI: 3.30. **Citations: 10. Q1**
50. Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, Draghici IA, **Balasa R**. Postpartum cerebral venous thrombosis – a single center experience. *Brain Sciences*. 2021;11:1-9. DOI: 10.3390/brainsci11030327. FI: 3.33. **Citations: 7. Q3**
51. Maier S, Simu M, Hutanu A, Barcutean L, Voidazan S, Bajko Z, Motataianu A, Lata I, **Balasa R**. Clinical immunological correlations in patients with multiple sclerosis treated with natalizumab. *Brain sciences*. 2020;10:1-11. DOI: 10.3390/brainsci10110802. FI: 3.33. **Citations 2. Q3**
52. **Balasa R**, Barcutean L, Balasa A, Motataianu A, Roman-Filip C, Manu D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. *Human Immunology*. 2020;81:273-243. DOI: 10.1016/j.humimm.2020.02.009. FI: 2.41. **Citations: 61. Q3**
53. Stoian A, Motataianu A, Barcutean L, Maier S, Bajko Z, Voidazan S, Farcas A, **Balasa R**. Understanding the mechanism of action of intravenous Immunoglobulins: a ten years' experience in treating Guillain barré syndrome. *Farmacia*. 2020;68:426-435. FI: 1.60. **Citations: 10. Q4**
54. Romaniuc A, **Bălașa R**, Știrbu N, Maier S, Andone S, Bajko Z, Bărcuțean L, Voidăzan S, Moțățăianu A. The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients. *Behavioural Neurology*. 2020, Article ID 2594702, DOI: 10.1155/2020/2594702. FI: 1.90. **Citations 5. Q2**
55. **Balasa R**. Therapeutic Plasma Exchange: An Indispensable Therapy for Severe Neurological Condition. *J Crit Care Med (Targu Mures)*. 2020 May 6;6(2):89-90. **ESCI**
56. Moțățăianu A, Bărcuțean L, **Bălașa R**. Neuroimmunity in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2020, 0: 1-8. DOI: 10.1080/21678421.2019.1708949. FI: 2.88. **Citations: 11. Q2**
57. Hutanu A, Iancu M, Maier S, **Balasa R**, Dobreanu M. Plasma biomarkers as potential predictors of functional dependence in daily life activities after ischemic stroke: A single center study. *Ann Ind Acad Neurol*. 2020;23:496-503. Doi:10.4103/aian.AIAN\_74\_19. FI: 0.89. **Citations: 2. Q4**
58. **Bălașa R**, Maier S, Bărcuțean L, Stoian A, Moțățăianu A. The direct deleterious effect of Th17 cells in the nervous system compartment in multiple sclerosis and experimental autoimmune

- encephalomyelitis: one possible link between neuroinflammation and neurodegeneration. *Revista Română de Medicină de Laborator* 2020, 28 (1), DOI:10.2478/rmlm-2020-0005. FI: 0.80. **Citations: 1. Q4**
59. Maier S, Moțățianu A, Bărcuțean L, Balint A, Huțanu A, Bajko Z, Stoian A, Romaniuc A, Andone S, **Bălașa R**. Interferon- $\beta$  1a, an immunomodulator in relapsing remitting multiple sclerosis patients. The effect on pro-inflammatory cytokines. *Farmacia* 2020, 68 (1). DOI:10.31925/farmacia.2020.1.10, FI: 1.52. **Citations: 2. Q4**
  60. Bajkó Z, Andone S, Buruian M, Filep R, **Bălașa R**. Unilateral deep cerebral venous sinus thrombosis with reversible secondary parkinsonism. *Acta Neurol Belgica*. Epub 2018. 2020;120:503-506. DOI: 10.1007/s13760-018-0982-0. FI: 1.61. Citations: 2. **Q3**
  61. Hutanu A, Iancu M, Dobreanu M, Oprea OR, Barbu S, Maier S, Tero-Vescan A, Bajko Z, **Balasa R**. Extended lipid profile in Romanian ischemic stroke patients in relation to stroke severity and outcome: a path analysis model. *Arch Med Sci* 2019; <https://doi.org/10.5114/aoms.2019.89302>. FI: 2.28.
  62. Karelis G, **Balasa R**, De Bleecker J, Stuchevskaya T, Villa An, Van Damme P, Lagrange E, Heckmann JM, Nicolle M, Vilciu C, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubi S, Ayaguanosa J. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. *Eur Neurol*. 2019;81(5-6):223-230. FI: 1.2. **Citations: 6.**
  63. Bajko Z, Filep RC, Maier S, Motaitianu A, Andone S, **Balasa R**. Bilateral vertebral artery without stroke secondary to giant cell arteritis. *Acta Reumatol Port* 2019; 44:155-157. FI: 0.77.
  64. Maier S, Copotioiu M, Romaniuc A, Andone S, **Bălașa R**. Central-variant reversible encephalopathy syndrome in a young patient with systemic lupus erythematosus. *Acta Neurol Belgica* 2019; 119: 269-271. FI: 1.61. **Q3**
  65. Bărcuțean LI, Romaniuc A, Maier S, Bajkó Z, Moțățianu A, Huțanu A, Simu I, Andone S, **Bălașa R**. Clinical and serological biomarkers of treatment's response in patients treated continuously with interferon $\beta$ -1b for more than a decade. *CNS Neurol Disord Drug-Targets* 2018; 17: 720-792. FI: 2.08. **Citations: 14. Q4**
  66. Moțățianu A, Maier S, Bajkó Z, Voidazan S, **Bălașa R**, Stoian A. Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. *BMC Neurology* 2018; 18: 126. Doi: 10.1186/s12883-018-1125-1. FI: 2.48. Citations: 12.
  67. Bajkó Z, Maier S, Moțățianu A, **Bălașa R**, Vasiu S, Stoian A, Andone S. Stroke Secondary to Traumatic Carotid Artery Injury - A Case Report. *J Crit Care Med (Targu Mures)*. 2018 Feb 9;4(1):23-28. **ESCI**
  68. **Bălașa R**, Ciurba B, Voidazan S, Simu I, Huțanu A, Andone S, Romaniuc A, Moțățianu A, Maier S. The matrix metalloproteinases panel in multiple sclerosis patients treated with Natalizumab: A possible answer to Natalizumab non-responders. *CNS Neurol Disord Drug-Targets* 2018; 17: 464-472. FI: 2.08. Citations: 10. **Q4**
  69. Huțanu A, Iancu M, **Bălașa R**, Maier S, Dobreanu M. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. *Acta Pharmacol Sin* 2018; 39: 1228-1236. FI: 0.99. Citations: 13.
  70. Huțanu A, Maier M, **Bălașa R**, Oprea OR, Barbu Ș, Voidăzan S, Dobreanu M. Plasma phosphorylated neurofilament heavy chains as a potential marker for ischemic stroke patients. *Rom J Lab Med* 2018; 26: 59-64. DOI: <https://doi.org/10.2478/rmlm-2018-0004>. FI: 0.32. **Citations: 2. Q4**
  71. **Bălașa R**, Simu M, Voidăzan S, Bărcuțean LI, Bajko Z, Huțanu A, Simu I, Maier S. Natalizumab changes the peripheral profile of the Th17 panel in MS patients: New mechanisms of action. *CNS Neurol Disord Drug-Targets* 2017; 16: ISSN: 1018-1026. FI: 2.18. **Citations: 23. Q4**
  72. Maier S, **Bălașa R**, Bajkó Z, Simu I, Horvath E. Complete progressive ophthalmoplegia and numb chin syndrome, the first clinical manifestations of a lethal abdominal Burkitt lymphoma. *Neurol Neurochir Polska* 2017; 51: 510-513. FI: 0.85. **Citations: 3.**
  73. Gál R, **Bălașa R**, Bajkó Z, Maier S, Simu I, Bălașa A. Lethal Subarachnoid and Intracerebral Haemorrhage Associated with Temporal Arteritis. A Case Report. *J Crit Care Med (Targu Mures)*. 2017 Nov 8;3(4):153-157. **ESCI**
  74. **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățianu A, Țilea B, Tiu C. Assessment of interleukin-17A, interleukin-10 and transforming growth factor-beta 1 serum titers in relapsing remitting multiple sclerosis patients treated with Avonex, possible biomarkers for treatment response. *CNS Neurol Disord Drug-Targets* 2017; 16: 93-101. FI: 2.18. **Citations: 18. Q4**
  75. Țilea B, Voidăzan S, **Bălașa R**, Huțanu A, Fodor A. CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of central nervous system. *Rom J Lab Med* 2017; 25: DOI:10.1515/rmlm-2016-0043. FI: 0.32. **Citations: 1. Q4**
  76. **Bălașa R**. The Eleventh Hour: Neurosyphilis, Still Fashionable but a Controversial Diagnosis. *J Crit*

- Care Med (Targu Mures). 2017 May 11;3(2):53-54. **ESCI**
77. Bajkó Z, Maier S, Moțățaiianu A, Stoian A, Bărcuțean L, **Bălașa R**. Repetitive Transient Ischaemic Attacks Secondary to a Floating Carotid Artery Thrombus in a Young Patient with Essential Thrombocythemia. *Journal of Cardiovascular Emergencies*. 2016;2:188-191. **ESCI**
  78. Mărginean A, Bălănescu C, Moldovan V, Scridon A, Mărginean M, **Bălașa R**, Maier S, Țăruși M, Dobreanu M. The impact of CY2C19 polymorphism, clinical and demographic variables on platelet response to clopidogrel evaluated using impedance aggregometry. *Clin Appl Thromb/Hemost* 2017; 23: 255-265. FI: 2.39. **Citations: 17.**
  79. Maier S, Bajkó Z, Moțățaiianu A, Rusu S, **Bălașa R**. Giant internal carotid artery aneurysm causing Collet-Sicard syndrome. *Acta Neurol Belgica* 2017; 117: 295-297. FI: 0.89. **Citations: 3. Q3**
  80. Bălașa A, **Bălașa R**, Egyed-Zsigmond I, Chinezu R. Bilateral thalamic glioma: case report and review of the literature. *Turk Neurosurg* 2016; 26: 321-324. FI: 0.57. **Citations: 5.**
  81. Bajkó Z, **Bălașa R**, Moțățaiianu A, Bărcuțean L, Stoian A, Stirbu N, Maier S. Malignant Middle Cerebral Artery Infarction Secondary to Traumatic Bilateral Internal Carotid Artery Dissection. A Case Report. *J Crit Care Med (Targu Mures)*. 2016 Aug 10;2(3):135-141. **ESCI**
  82. **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățaiianu A. An intricate mechanism of action of Avonex in relapsing remitting multiple sclerosis patients: variation of serum titre of interleukin-17A, interleukin-10 and transforming growth factor-beta. *CNS Neurol Disord Drug Targets* 2015; 14: 804-810. FI: 2.70. **Citations: 7. Q4**
  83. **Bălașa R**, Maier S, Bajkó Z, Pașcanu I, Moțățaiianu A. Skeletal muscle Na<sup>+</sup>/K<sup>+</sup>-ATPase pump dysfunction in thyrotoxic periodic paralysis: case report. *Acta Endocrinol (Buc)* 2015; 11: 240-245. FI: 0.21. **Citations: 2.**
  84. **Bălașa R**, Maier S, Bajkó Z, Moțățaiianu A, Crișan A, Bălașa A. Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review. *Acta Neurol Belgica* 2015; 115: 635-642. FI: 0.598. **Citations: 4. Q4**
  85. Maier S, Buruian M, Maier A, Moțățaiianu A, Voidăzan S, Bajkó Z, **Bălașa R**. The determinants of depression in a Romanian cohort of multiple sclerosis patients. *Acta Neurol Belgica* 2015; DOI: 10.1007/s13760-015-0547-4. FI: 0.59. **Citations: 8. Q4**
  86. Bajkó Z, **Bălașa R**, Szatmári S, Rusu S, Moțățaiianu A, Maier S. The role of ultrasound in the diagnosis of temporal arteritis. *Neurol Neurochir Polska* 2015; 49: 139-143. FI: 0.64. **Citations: 2.**
  87. Stoian A, Bănescu C, **Bălașa R**, Moțățaiianu A, Stoian M, Moldovan VG, Voidăzan S, Dobreanu M. Influence of GSTM1, and GSTP1 polymorphisms on type 2 diabetes mellitus and diabetic sensorimotor peripheral neuropathy risk. *Dis Markers* 2015; ID 638693. FI: 1.56. **Citations: 23.**
  88. Jung I, Gurzu S, **Bălașa R**, Moțățaiianu A, Contac AO, Halmaciu I, Popescu S, Simu I. A coin-like peripheral small lung carcinoma associated with acute paraneoplastic axonal Guillain-Barré-like syndrome. *Medicine (Baltimore)* 2015; 94: e910. FI: 4.25. **Citations:12. Q2**
  89. **Bălașa R**, Maier S, Gliga Baubec E, Bajkó Z, Bălașa A. Cerebellar and brainstem variant of posterior reversible encephalopathy syndrome. *Acta Neurol Belg* 2015; 115: 401-403. FI: 0.59. **Citations:1. Q4**
  90. **Bălașa R**, Bajkó Z, Moțățaiianu A, Maier A, Maier S. Neuromyelitis optica associated with painful dystonia: case report and literature review. *Acta Neurol Belg* 2015; 115: 169-171. FI: 0.59. **Citations:1. Q4**
  91. **Bălașa R**, Maier S, Moțățaiianu A, Bajkó Z, Moldovan O, Benedek E. A case of fatal acute intermittent porphyria: laboratory diagnosis and pathogenesis considerations. *Rev Rom Med Lab* 2014; 22: 325-333. FI: 0.17. **Citations:1. ESCI**
  92. Treabă AC, **Bălașa R**, Podoleanu DM, Simu IP, Buruian MM. Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? *Diagn Interv Radiol* 2014; 20: 178-184. FI: 1.42. **Citations: 9. Q4 SCIE**
  93. Moțățaiianu A, **Bălașa R**, Voidăzan S, Bajkó Z. Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus. *BioMed Res Internat* 2013, Article ID 507216. FI: 2.70. **Citations:11. Q4**
  94. **Bălașa R**, Bajkó Z, Huțanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. *Mult Scler J* 2013; 19:885-890. FI: 4.863. **Citations: 27. Q1**
  95. **Bălașa R**, Huțanu A, Bajkó Z, Feier C, Pascu I. Does the serum IL-17 titer influence the efficacy of interferon-beta treatment in multiple sclerosis? *Rom J Lab Med* 2011; 19: 381-389. IF: 0.091. **Citations:10. ESCI**
  96. **Bălașa R**, Huțanu A, Feier C, Bajkó Z, Pascu I. Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon-β treatment in multiple sclerosis patients. *Rom J Lab Med* 2010; 18: 39-50. IF: 0.113. **Citations: 2. ESCI**

